CONSTITUENT REPORT
octanal
Octanal is a classic medium-chain aldehyde that contributes sparkling citrus-peel lift to orange, grapefruit, mandarin, and related peel oils while also carrying the waxy-fatty edge typical of straight aliphatic aldehydes. The evidence base is solid for identity, aroma significance, and current fragrance-safety review status. Mechanistic literature is more mixed: octanal appears in odor-receptor and inflammation research and in some antimicrobial screening systems, but those findings do not support wellness claims and may point to context-dependent biological activity rather than consumer benefit.
Chemical identity and composition
PubChem and the NIST Chemistry WebBook identify octanal as the straight-chain C8 aldehyde C8H16O. It is widely used in flavor and fragrance work under names such as n-octanal, caprylaldehyde, and aldehyde C-8.
Aroma and practical use
- Use the recorded citrus peel, fatty, green, waxy, soapy, orange peel, fresh descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2022 Science paper reported that octanal activated mouse Olfr2 and human OR6A2 in macrophages, induced NLRP3 inflammasome signaling and IL-1beta secretion, and worsened atherosclerosis when octanal levels were increased in mice.
This is the strongest constituent-specific mechanistic paper located for octanal, and it argues for cautious non-benefit framing because the biology described is pro-inflammatory in that context.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2022 review on olfactory receptors in macrophages summarized that triggering human OR6A2 or mouse Olfr2 with octanal induces inflammasome assembly and IL-1beta secretion and noted positive associations between octanal and blood lipid markers.
This is useful secondary support because it consolidates the emerging extranasal odor-receptor literature around octanal.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A redblush grapefruit volatile study listed octanal among the main constituents at roughly 0.1-0.5%, reinforcing its role as a minor-percentage but aroma-relevant citrus aldehyde.
This supports why octanal matters in aroma despite low concentration: aldehydes can shape topnote character disproportionate to their percentage.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2025 Food and Chemical Toxicology record documents a dedicated RIFM fragrance ingredient safety assessment for octanal, confirming that the compound remains under contemporary fragrance safety review.
The abstract text retrieved here mainly confirms the existence of the formal safety assessment rather than exposing a detailed endpoint-by-endpoint conclusion.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
A 2025 RIFM fragrance ingredient safety assessment exists for octanal, making formal fragrance-safety review the strongest current standalone safety anchor found in this pass.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
Octanal's clearest constituent-specific mechanism literature in this pass was pro-inflammatory macrophage signaling rather than consumer benefit, so archive messaging should remain descriptive and non-medical.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
This pass did not verify robust human efficacy or wellness data for isolated octanal.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
nootkatoneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
aroma science · whole_oil
No source citation attached.
Read nootkatone report →How the effects were investigated
or6a2_olfr2_triggered_nlrp3_inflammasome_activation
A 2022 Science paper and a 2022 macrophage review describe octanal as a ligand for Olfr2 and human OR6A2 that can trigger NLRP3 inflammasome assembly and IL-1beta secretion in macrophages.
This experimental finding does not establish benefit, dose or safety in people using this blend.
aldehyde_reactivity_in_antimicrobial_screening
Aldehyde-focused antimicrobial literature supports the broader idea that reactive aldehydic structures can disrupt microbial systems, although the accessible octanal-specific evidence here is limited and indirect.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- This pass did not verify strong human clinical efficacy evidence for isolated octanal.
- Octanal-specific antimicrobial literature was thinner and less directly relevant than the inflammation-signaling literature.
- The accessible abstract for the 2025 RIFM safety assessment confirmed review status more clearly than detailed public endpoint conclusions.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.